China Shineway Pharmaceutical Group (HKG:2877) Full Year 2024 Results
Key Financial Results
- Revenue: CN¥3.78b (down 16% from FY 2023).
- Net income: CN¥840.1m (down 13% from FY 2023).
- Profit margin: 22% (in line with FY 2023).
- EPS: CN¥1.11 (down from CN¥1.28 in FY 2023).
2877 Products In Clinical Trials
- Phase III: 3.
All figures shown in the chart above are for the trailing 12 month (TTM) period
China Shineway Pharmaceutical Group Revenues and Earnings Miss Expectations
Revenue missed analyst estimates by 6.8%. Earnings per share (EPS) also missed analyst estimates by 11%.
In the last 12 months, the only revenue segment was Chinese Pharmaceutical Products contributing CN¥3.78b. The largest operating expense was Sales & Marketing costs, amounting to CN¥1.60b (80% of total expenses). Over the last 12 months, the company's earnings were enhanced by non-operating gains of CN¥4.06m. Explore how 2877's revenue and expenses shape its earnings.
Looking ahead, revenue is forecast to grow 8.3% p.a. on average during the next 3 years, compared to a 8.7% growth forecast for the Pharmaceuticals industry in Hong Kong.
Performance of the Hong Kong Pharmaceuticals industry.
The company's shares are up 2.2% from a week ago.
Risk Analysis
You should learn about the 1 warning sign we've spotted with China Shineway Pharmaceutical Group.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.